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Abstract 
Background: Small hepatocellular carcinoma (sHCC) is a unique variant of HCC that is characterized by small tumor 
size (maximum tumor diameter ≤3 cm) and favorable long‑term outcomes. The present study aimed to define clin‑
icopathologic factors that predict survival in patients with sHCC.
Methods: The study population consisted of 335 patients who underwent hepatectomy for solitary sHCC between 
December 1998 and 2010. Prognostic factors were evaluated using Kaplan–Meier curves and Cox proportional hazard 
models.
Results: The 5‑year overall survival (OS) and recurrence‑free survival (RFS) rates were 77.7% and 59.9%, respectively. 
Kaplan–Meier curves showed that tumor size and vascular invasion had prognostic significance within this relatively 
selected cohort (P < 0.05). Multivariate analysis confirmed that increased tumor size and vascular invasion were 
independent prognostic factors for short OS (hazard ratio [HR] = 2.367, 95% confidence interval [CI] 1.406–3.985; 
HR = 2.954, 95% CI 1.781–4.900) and RFS (HR = 1.779, 95% CI 1.259–2.514; HR = 1.699, 95% CI 1.165–2.477) in sHCC 
patients (P < 0.05). Importantly, a proposed prognostic scoring model was derived according to the two variables; 
tumor size and extent of vascular invasion were significantly associated with OS and RFS in patients with sHCC 
(P < 0.001).
Conclusions: Tumor size and vascular invasion are feasible and useful prognostic factors for sHCC. The proposed 
prognostic model, based on tumor size and vascular invasion, is informative in predicting survival in sHCC patients 
undergoing hepatectomy.
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Background
Hepatocellular carcinoma (HCC) is the third leading 
cause of cancer-related deaths worldwide [1]. HCC has 
a high prevalence in Southeast Asia and Africa [2], and 
the incidence has been steadily increasing in both Europe 
and the United States [3]. Liver cirrhosis, particularly as 
a consequence of hepatitis B virus (HBV) and hepatitis C 
virus (HCV) infection, is the most common risk factor for 
the development of HCC [4]. Due to the high prevalence 
of HBV infection among Chinese populations, there are 
a significant number of deaths due to HBV-related HCC 
in China [5]. Surveillance and recent advances in imaging 
techniques have resulted in improved identification and 
diagnosis of small HCC (sHCC, ≤3 cm in diameter) [6, 7].
Early detection of HCC allows for curative or palliative 
treatment with surgical resection or transcatheter arte-
rial chemoembolization [8]. Currently, surgical resec-
tion offers the greatest chance for cure; however, many 
patients still suffer from disease recurrence after primary 
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treatment [9, 10]. It is imperative to identify patients at 
high risk for optimal follow-up or postoperative adjuvant 
therapies in these patients [11, 12]. The known risk fac-
tors for sHCC enable the identification and screening of 
patients at high risk for HCC; however, prognosis-related 
factors are yet to know, which would enable stratification 
of sHCC patients into treatment groups following hepa-
tectomy [13–15]. Clinicopathologic features are the main 
factors affecting postoperative survival of patients with 
sHCC. The current study was to identify clinicopatho-




Data were obtained from the Sun Yat-sen University 
Cancer Center (Guangzhou, China) for cases of patho-
logically confirmed, non-metastatic sHCC between 
December 1998 and 2010. Only patients who underwent 
surgical resection, not ablation or transplantation, as 
the first course of therapy were included in the present 
study. Case data were collected retrospectively using the 
following eligibility criteria: (1) solitary sHCC (≤3  cm) 
only, (2) presence of the HBV surface antigen, (3) patient 
underwent primary and curative resection, (4) no evi-
dence of metastatic or residual disease, (5) no preop-
erative adjuvant therapy, and (6) availability of complete 
follow-up data. Patients with unknown cause of death 
were excluded. All patients underwent curative resec-
tion for HCC with the following intraoperative goals: 
a resection margin  >1  cm, complete tumor resection, 
and leaving the resection margin free of tumor. All the 
patients included in our study were previously diagnosed 
by senior pathologists, and the histopathologic diagno-
sis was re-confirmed independently by an experienced 
pathologist (Mu-Yan Cai). The extent of tumor differen-
tiation was determined based on the criteria proposed 
by Edmonson and Steiner [16]. Vascular invasion in 
each HCC specimen was identified in several serial cross 
sections. Patients who had macroscopic and/or micro-
scopic tumor emboli within the large capsular vessels, 
the central hepatic vein, or the portal vein were consid-
ered to have vascular invasion. Cirrhosis was defined by 
the presence of fibrous septa throughout the liver that 
subdivided the parenchyma into nodules. The Institu-
tional Research Medical Ethics Committee of the Sun 
Yat-sen University Cancer Center granted approval for 
this study. No informed consent (written or verbal) was 
obtained for the use of retrospective tissue samples from 
the patients in this study, most of whom were deceased. 
Consent was not deemed necessary by the Ethics Com-
mittee, who waived the need for consent, however all 
samples were anonymized.
Follow‑up
After partial hepatectomy, patient follow-up was per-
formed at 2–6  month intervals at the outpatient clinic 
with regular surveillance for recurrence using serum 
alpha-fetoprotein (AFP) examination, abdominal ultra-
sonography, and chest radiography. In cases where tumor 
recurrence or metastasis was suspected, further exami-
nations, including computed tomography (CT) and mag-
netic resonance imaging (MRI), were performed. Biopsies 
were obtained when necessary. Recurrence-free survival 
(RFS) was calculated from the date of surgery to the first 
documentation of cancer recurrence. Cancer-specific 
overall survival (OS) was calculated from the date of sur-
gery to the date of the last follow-up visit (January 18, 
2014) or time of death attributed to HCC.
Statistical analysis
Kaplan–Meier analysis with a log-rank test was per-
formed to compare the survival distributions of different 
variables. Multiple Cox proportional hazard regression 
was performed to identify the independent factors that 
had a significant impact on patient survival. All statisti-
cal analyses were conducted using SPSS for Windows 
version 13.0 release (SPCC Inc., Chicago, IL, USA). A dif-
ference was considered significant if the P value from a 
two-tailed test was less than 0.05.
Results
Patient characteristics
Using the criteria described above, 335 cases of sHCC 
were included in this study. Demographic and clinical 
findings for these patients are presented in Table  1. Of 
the 335 patients, 295 (88.1%) were men, and 40 (11.9%) 
were women, with a median age of 48  years (range, 
26–78  years). Among the 335 patients, 196 (58.5%) had 
serum AFP levels  >20  ng/mL. The median tumor size 
was 2.5 cm (range, 0.6–3.0 cm). Most patients exhibited 
well-differentiated or moderately-differentiated tumors 
(n =  264, 78.8%). Vascular invasion was observed in 80 
(23.9%) patients, characterized by clusters of tumor 
cells localized to vascular spaces, and interspersed with 
blood cells. A total of 121 (36.1%) tumors were encapsu-
lated. Liver cirrhosis was present in 134 (40.0%) patients. 
Patients with confirmed tumor recurrence underwent re-
resection when possible, or were treated with transcath-
eter arterial chemoembolization, percutaneous ethanol 
injection, or radiofrequency ablation.
Prognostic factors affecting postoperative survival 
of patients with sHCC
Of the 335 patients, 131 (39.1%) experienced HCC 
recurrence, and 62 (18.5%) died during the follow-up 
period. The median OS and RFS were 44 and 36 months. 
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The 5-year OS and RFS rates were 77.7% and 59.9%. 
Descriptive survival statistics and Kaplan–Meier analy-
sis suggested that tumor size and vascular invasion had 
prognostic significance within this selected cohort. 
Tumor size >2.5 cm was associated with lower 5-year OS 
and RFS rates as compared with tumor size ≤2.5 cm (OS: 
67.3% vs. 87.0%, hazard ratio [HR] =  2.431, 95% confi-
dence interval [CI] = 1.443–4.093, P = 0.014; RFS: 50.3% 
vs. 67.6%, HR =  1.710, 95% CI 1.211–2.415, P =  0.002) 
(Table  2; Fig.  1a, b). Similarly, the 5-year OS and RFS 
rates were higher in patients without vascular inva-
sion than in patients with vascular invasion (OS: 83.2% 
vs. 59.2%, HR =  3.033, 95% CI 1.827–5.035, P =  0.001; 
RFS: 63.7% vs. 47.2%, HR = 1.790, 95% CI 1.236–2.594, 
P = 0.002) (Table 2; Fig. 1c, d). Additionally, tumor grade 
was significantly associated with RFS (P = 0.003), but not 
with OS (P = 0.172) (Table 2; Fig. 1e, f ).
Multivariate Cox regression analysis
The clinicopathologic variables were examined using 
multivariate Cox regression analysis. The multivariate 
analysis confirmed that tumor size >2.5 cm (HR = 2.367, 
95% CI 1.406–3.985, P  =  0.001) and vascular inva-
sion (HR = 2.954, 95% CI 1.781–4.900, P < 0.001) were 
independent prognostic factors for short OS in patients 
with sHCC (Table  3). Similarly, tumor size  >2.5  cm 
(HR = 1.779, 95% CI 1.259–2.514, P = 0.001) and vascu-
lar invasion (HR = 1.699, 95% CI 1.165–2.477, P = 0.006) 
were shown to be independent and powerful predictors 
for RFS (Table 3).
New prognostic model of tumor size and vascular invasion 
in sHCC
Based on the results of our univariate and multivariate 
analyses, we proposed a new clinicopathologic prog-
nostic model with two prognostic factors: tumor size 
and vascular invasion. We therefore designated a high-
risk group with the presence of both factors (tumor 
size >2.5 cm and presence of vascular invasion), an inter-
mediate-risk group with the presence of either factor 
(regardless of their identity), and a low-risk group with 
neither factor. This model successfully stratified risk (low, 
intermediate, and high) for OS and RFS prediction (both 
P < 0.001, Fig. 2).
Discussion
In the present study, we have investigated the prognos-
tic predictors in a large cohort of patients from an area 
of high prevalence of HBV infection and who underwent 
liver resection for sHCC. Importantly, tumor size and 
vascular invasion were independent prognostic factors 
determining the outcome of these patients, and a prog-
nostic scoring model derived according to these two vari-
ables was shown to accurately predict survival in patients 
with sHCC.
Tumor size is a well-known risk factor for survival after 
hepatectomy for HCC [17–19]. However, the appropri-
ate tumor size cutoff for prognosis predicting has been 
debated at length. Several studies have indicated that 
a tumor size >5 cm is of prognostic significance only in 
patients with multifocal tumors [19]. In contrast, Mina-
gawa et  al. [17] showed a significant difference in sur-
vival between patients with tumors <2 cm and those with 
tumors measuring 2–5  cm, irrespective of multifocality 
or vascular invasion. Moreover, Zhou et al. [20] reported 
that tumor size significantly associated with decreased 
OS; the 5-year OS rates for patients with sHCC tumors 
Table 1 The characteristics of  335 patients with  small 
hepatocellular carcinoma (sHCC)
ALT alanine aminotranferease, AFP alpha-fetoprotein
Variable No. of patients (%)
Gender
 Male 295 (88.1)
 Female 40 (11.9)
Age (years)
 ≤48 166 (49.6)
 >48 169 (50.4)
ALT (U/L)
 ≤40 192 (57.3)
 >40 143 (42.7)
AFP (ng/mL)
 ≤20 139 (41.5)
 >20 196 (58.5)
Tumor size (cm)
 ≤2.5 188 (56.1)
 >2.5 147 (43.9)
Tumor differentiation
 Well 56 (16.7)
 Moderate 208 (62.1)
 Poor 63 (18.8)
 Undifferentiated 8 (2.4)
Vascular invasion
 Absent 255 (76.1)
 Present 80 (23.9)
Envelope
 Absent 214 (63.9)
 Present 121 (36.1)
Liver cirrhosis
 Absent 201 (60.0)
 Present 134 (40.0)
Recurrence
 Absent 204 (60.9)
 Present 131 (39.1)
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measuring  ≤2.0, 2.1–3.0, and 3.1–5.0  cm were 82.5%, 
66.3%, and 61.2%, respectively. Similarly, we found that 
tumor size  >2.5  cm was associated with a short OS or 
RFS, even within a cohort of patients with tumors ≤3 cm. 
However, Nanashima et  al. [21] reported no significant 
difference in OS between patients with solitary sHCC 
tumors <2 cm and those with tumors measuring 2–3 cm 
in size. Lu et  al. [22] observed no significant difference 
in OS and RFS between patients with tumors measur-
ing 1.1–2.0 and 2.1–3.0  cm. Taken together, differences 
in the clinicopathologic characteristics among cohorts, 
geographic backgrounds, tumor size cutoff, patient het-
erogeneity, small sample sizes, and different definitions of 
end points (OS or RFS) may contribute to the conflicting 
results. In our study, the findings of a significant associa-
tion between tumor size and clinical outcome in sHCC 
patients may be strengthened by the consistent resec-
tion procedure and large sample size. Moreover, the rate 
of liver cirrhosis was 40% in the present study, which is 
much lower than that observed in previous studies of 
Chinese populations [23, 24]. Only patients with sHCC 
(≤3  cm) were included in our study, and this group is 
generally considered to have early stage HCC. This is one 
potential explanation for the low incidence of liver cir-
rhosis observed in the present study.
HCC is characterized by a propensity for vascular 
invasion [23], and vascular invasion is a clinicopatho-
logic feature related to aggressive biological behavior of 
HCC. Over the past several decades, multiple studies 
have shown that vascular invasion is a strong predictor 
of outcome following hepatic resection and liver trans-
plantation for HCC. Nevertheless, the relative prognostic 
importance of vascular invasion in sHCC remains con-
troversial, and there is significant inter-study and intra-
study variability in assessing vascular invasion. Shindoh 
et  al. [25] reported that vascular invasion did not affect 
survival of patient with sHCC (≤2  cm), whereas others 
maintain the opposing view that vascular invasion is an 
independent prognostic factor for sHCC (≤3  cm) [26]. 
Our data showed that vascular invasion had an adverse 
effect on long-term survival in patients with sHCC. The 
presence of vascular invasion was associated with a sig-
nificant decrease in both 5-year OS and RFS rates. How-
ever, a crossover exists in RFS curves between patients 
with and without vascular invasion. We thought that the 
individual differences of cohorts and the different effects 
of vascular invasion on short-term and long-term sur-
vival would have contributed to this crossover. Based on 
a meta-analysis of our results as well as those of other 
studies, the presence of vascular invasion is associated 
with an adverse prognosis in HCC [27]. An international 
consensus on precisely what is meant by vascular inva-
sion in HCC could provide a more consistent assessment 
and therefore a more reliable prediction of prognosis and 
a better understanding of the pathophysiology of HCC 
angioinvasion.
The reported OS rates for patients with HCC follow-
ing resection varies widely in the literature, with 5-year 
OS rates ranging from 35% to 70% [28–30]. Patients 
with sHCC are generally thought to have a good out-
come and are often considered a relatively homogeneous 
group. Data from our study revealed that even patients 
with early-stage HCC could be stratified into sub-
groups with distinct long-term prognoses. An improved 
understanding of the factors that affect outcome in this 
group of patients may impact choice of follow-up strate-
gies and salvage therapy as well as guiding future stud-
ies [13]. In this study, we analyzed data from a large, 
population-based cohort of patients with pathologi-
cally proven sHCC. The apparent homogeneity of this 
Table 2 Univariate analysis of different prognostic factors for survival in 335 patients with sHCC (Cox proportional haz-
ards regression)
AFP alpha-fetoprotein, ALT alanine aminotranferease, HR hazards ratio, CI confidence interval
Variable Overall survival Recurrence‑free survival
HR (95% CI) P value HR (95% CI) P value
Gender (male vs. female) 0.825 (0.374–1.816) 0.825 0.663 (0.366–1.202) 0.176
Age (>48 vs. ≤48 years) 1.014 (0.615–1.672) 0.331 1.171 (0.829–1.654) 0.371
ALT (≤40 vs. >40 U/L) 1.337 (0.812–2.201) 0.949 1.272 (0.902–1.795) 0.170
AFP (≤20 vs. >20 ng/mL) 1.230 (0.734–2.059) 0.130 0.912 (0.644–1.289) 0.601
Tumor size (≤2.5 vs. > 2.5 cm) 2.431 (1.443–4.093) 0.014 1.710 (1.211–2.415) 0.002
Tumor differentiation (well‑moderate vs. poor‑undifferentiated) 1.215 (0.679–2.175) 0.172 1.774 (1.221–2.578) 0.003
Vascular invasion (absent vs. present) 3.033 (1.827–5.035) 0.001 1.790 (1.236–2.594) 0.002
Envelope (absent vs. present) 0.920 (0.544–1.559) 0. 110 0.958 (0.668–1.375) 0. 816
Liver cirrhosis (absent vs. present) 1.516 (0.921–2.495) 0.496 1.329 (0.939–1.881) 0.108
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cohort with respect to extent of disease (≤3 cm in size, 
solitary tumor, and no nodal involvement or metasta-
ses) and surgical resection was notable. Despite this, we 
found that the 5-year OS rate in this group ranged from 
59.2% to 83.2%. In the current study, we found that the 
proposed prognostic model containing both tumor size 
and vascular invasion could reflect the aggressive pheno-
type of sHCC. Thus, this combined model may be a use-
ful prognostic indicator for sHCC. There are also intense 
ongoing efforts to integrate biomarkers into established 
clinicopathologic models to further improve their predic-
tive ability.
Fig. 1 Prognostic factors affecting postoperative survival of patients with small hepatocellular carcinoma (sHCC) (log‑rank test). a Tumor 
size >2.5 cm was associated with a decrease in overall survival (OS) of patients (P = 0.001). b Tumor size >2.5 cm was associated with a decrease in 
recurrence‑free survival (RFS) of patients (P = 0.002). c Tumor with vascular invasion was associated with a decrease in OS of patients (P < 0.001). d 
Tumor with vascular invasion was associated with a decrease in RFS of patients (P = 0.002). e Tumor with poor/undifferentiation was not sig‑
nificantly associated with a decrease in OS of patients (P = 0.511). f Tumor with poor/undifferentiation was associated with a decrease in RFS of 
patients (P = 0.002)
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Conclusions
Tumor size and vascular invasion are feasible and useful 
prognostic factors for solitary sHCC (≤3  cm). The pro-
posed prognostic model, based on tumor size and vas-
cular invasion, is informative to predict the survival in 
sHCC patients undergoing hepatectomy.
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